Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Galardi

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Oncotarget|April 18, 2018
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapyMartina Bonechi, Francesca Galardi, Chiara Biagioni, et al.
British Journal of Cancer|May 6, 2021
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective studyFrancesca Salvianti, Stefania Gelmini, Irene Mancini, et al.
JCO Precision Oncology|March 1, 2024
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd TrialIlenia Migliaccio, Dario Romagnoli, Francesca Galardi, et al.
NPJ Breast Cancer|March 8, 2025
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancerRiccardo Scandino, Agostina Nardone, Nicola Casiraghi, et al.
Briefings in Bioinformatics|January 18, 2023
MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samplesDario Romagnoli, Agostina Nardone, Francesca Galardi, et al.
Genome Medicine|February 4, 2026
A computational framework for sensitive tumor detection and accurate subtyping using shallow cell-free DNA methylome sequencingMarta Paoli, Francesca Galardi, Agostina Nardone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd TrialAmelia McCartney, Martina Bonechi, Francesca De Luca, et al.
Epidemiologia E Prevenzione|April 22, 2021
Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquineClaudia Lilli, Annibale Biggeri, Chiara Zingaretti, et al.
Breast Cancer Research : BCR|March 25, 2021
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trialFrancesca Galardi, Francesca De Luca, Chiara Biagioni, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2019
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)Amelia McCartney, Chiara Biagioni, Gaia Schiavon, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Oncotarget|April 18, 2018
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapyMartina Bonechi, Francesca Galardi, Chiara Biagioni, et al.
British Journal of Cancer|May 6, 2021
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective studyFrancesca Salvianti, Stefania Gelmini, Irene Mancini, et al.
JCO Precision Oncology|March 1, 2024
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd TrialIlenia Migliaccio, Dario Romagnoli, Francesca Galardi, et al.
NPJ Breast Cancer|March 8, 2025
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancerRiccardo Scandino, Agostina Nardone, Nicola Casiraghi, et al.
Briefings in Bioinformatics|January 18, 2023
MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samplesDario Romagnoli, Agostina Nardone, Francesca Galardi, et al.
Genome Medicine|February 4, 2026
A computational framework for sensitive tumor detection and accurate subtyping using shallow cell-free DNA methylome sequencingMarta Paoli, Francesca Galardi, Agostina Nardone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd TrialAmelia McCartney, Martina Bonechi, Francesca De Luca, et al.
Epidemiologia E Prevenzione|April 22, 2021
Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquineClaudia Lilli, Annibale Biggeri, Chiara Zingaretti, et al.
Breast Cancer Research : BCR|March 25, 2021
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trialFrancesca Galardi, Francesca De Luca, Chiara Biagioni, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2019
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)Amelia McCartney, Chiara Biagioni, Gaia Schiavon, et al.
Pageof 4